- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05905354
Clinical Study of HPV Therapeutic DNA Vaccine (NWRD08) in Patients With Cervical HPV16 and/or HPV18 Positive
June 6, 2023 updated by: Newish Technology (Beijing) Co., Ltd.
This is an open-label exploratory clinical study.
The main objective is to explore the immunogenicity of HPV therapeutic DNA vaccine NWRD08.
Study Overview
Detailed Description
The main objective is to explore the immunogenicity of HPV therapeutic DNA vaccine NWRD08.The secondary objective was to observe the safety of NWRD08 in cervical patients who were positive for HPV16 and/or HPV18, and to initially explore the efficacy of NWRD08.
Study Type
Interventional
Enrollment (Estimated)
12
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Liu Defang, Doctor
- Phone Number: (+86)010-87661655
- Email: ldf@newishes.com
Study Locations
-
-
Shandong
-
Heze, Shandong, China
- Recruiting
- Heze Municipal Hospital
-
Contact:
- Sun Guodong, Master
- Phone Number: (+86)0530-5613206
- Email: sunguodong0723@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age ≥18 years old;
- women who have sex;
- HPV16 and/or 18 DNA and E6E7 mRNA were positive;
- Patients with highly squamous intraepithelial lesions of the cervix confirmed by histology and cytology, or persistent cervical PV16 and/or 18 infection for more than 12 months;
- Cervical tissue specimens/sections should be provided 4 weeks before the first treatment of HISL;
- Electrocardiogram (ECG) is normal;
- Women of reproductive age must have a negative serum pregnancy test within 1 week prior to the first dose and have agreed to use effective contraception during the study drug use period and within 6 months after the last dose of the study drug. For males, it should be surgical sterilization or consent to effective contraception during the study drug use period and within 6 months after the last study drug administration;
- Have fully understood the study and voluntarily signed the ICF, be able to communicate well with the investigator and complete all treatments, examinations and visits required by the study protocol.
Exclusion Criteria:
- any histopathologically confirmed adenocarcinoma in situ (AIS), high-grade vulvar, vaginal or anal intraepithelial tumors, or invasive cancers;
- Patients with unsatisfactory colposcope;
- Patients who were satisfied with colposcopy but not satisfied with ECC (patients who were positive for HPV18 or had abnormal adenocytes on cervical cytology but satisfied with colposcopy should undergo ECC examination);
- Positive HPV type 31 or 33 or 45 or 52 or 58;
- Have received cervical physical therapy;
- pregnant, breastfeeding, or considering becoming pregnant during the study period;
- previous history of therapeutic or preventive HPV vaccination;
- Received any non-investigational inactivated vaccine injection within 2 weeks;
- Received any non-investigational live vaccine within 4 weeks;
- Acute or chronic bleeding or coagulopathy;
- Less than two sites can be used for intramuscular injection;
- Received chemotherapy, molecular targeted therapy, biological immunotherapy, or Chinese patent drugs for cervical lesions within 30 days before or during screening;
- participated in other clinical trials within 30 days prior to screening, or was in the observation period of other clinical trials;
- Continuous (more than 1 week) glucocorticoid therapy (dose equivalent to prednisone > 10 mg/ day), except hormone replacement therapy and endotracheal administration;
- History of immune deficiency or autoimmune disease (such as rheumatoid joint disease, systemic lupus erythematosus, multiple sclerosis, etc.);
- with uncontrolled severe infection;
- Patients with a history of hepatitis B virus (HBV), hepatitis C virus (HCV) infection or human immunodeficiency virus (HIV) infection or syphilis carriers;
- Patients with severe other organ dysfunction or cardiopulmonary disease, including myocardial infarction, stroke, congestive heart failure, severe lung disease, metabolic diseases, wound healing abnormalities, ulcers or fractures;
- Epilepsy accompanied by medication (such as steroids or antiepileptic drugs);
- Previous or present malignant neoplasms;
- A history of severe allergies, or a history of allergic diseases, or an allergic constitution, or a severe iodine contrast allergy, meeting any of these criteria;
- serious mental disorders;
- A history of drug or alcohol abuse;
- A pregnant or lactating woman, or a woman of childbearing age who has a positive blood pregnancy test, or a patient of childbearing age and her spouse who is unwilling to take effective contraceptive measures during the clinical study period and within 6 months after the end of treatment;
- Patients deemed unsuitable for this clinical trial by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: lose dose,high dose
Four dose groups were set up: dose group 1, a single dose of 2mg, administered at week 0, 4 and 12, three times in total; Dose group 2, a single dose of 6mg, respectively at the 0, 4, 12 weeks, a total of 3 times; Dose group 3, a single dose of 2mg, was given at the 0, 2, 4, 12 weeks, a total of 4 times; Dose group 4, with a single dose of 6mg, was given 4 times at week 0, 2, 4 and 12, respectively.
There were 3 subjects in each group.
Climb from the low dose group to the high dose group.
|
Subjects in dose group 1 and 2 were intramuscularly injected with NWRD08 at week 0, week 4 and week 12 by electric pulse gene delivery instrument, respectively.
Subjects in dose group 3 and 4 were intramuscularly injected NWRD08 at week 0, week 2, week 4 and week 12 by electric pulse gene delivery instrument, respectively.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV 16/18 E6E7 specific immune response in peripheral blood after vaccination compared to before vaccination.
Time Frame: Week36
|
Analysis of immunogenicity data included the level, type, subtype, and time and duration of specific humoral and cellular immune responses in peripheral blood before and after vaccination.
|
Week36
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AEs)
Time Frame: End of study
|
Adverse Events (AEs), adverse events according to type, frequency, severity [according to the Classification Scale of Adverse Events in Clinical Trials for Preventive Vaccines issued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration in 2019], occurrence time, and severity.
And whether it's related to treatment.
|
End of study
|
proportion of patients with HPV virus clearance
Time Frame: Week 36
|
Proportion of patients with negative HPV16/18 DNA and E6E7 mRNA.
|
Week 36
|
proportion of patients with regression of cervical lesions
Time Frame: Week 36
|
|
Week 36
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Sun Guodong, Master, Shandong Heze Municipal Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 7, 2022
Primary Completion (Estimated)
June 30, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
May 23, 2023
First Submitted That Met QC Criteria
June 6, 2023
First Posted (Actual)
June 15, 2023
Study Record Updates
Last Update Posted (Actual)
June 15, 2023
Last Update Submitted That Met QC Criteria
June 6, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- NEWISH-HPV-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HSIL of Cervix
-
Antiva BiosciencesCompletedCervical Cancer | Human Papilloma Virus | HSIL, High Grade Squamous Intraepithelial Lesions | Cervical Dysplasia | HSIL of Cervix | High-Grade Cervical Intraepithelial Neoplasia | HIV Negative | CIN - Cervical Intraepithelial Neoplasia | Cervical NeoplasmSouth Africa
-
Erasmus Medical CenterDutch Cancer SocietyNot yet recruitingHPV | Vulvar HSILNetherlands
-
Bnai Zion Medical CenterUnknownInduction of Labor | Unfavorable CervixIsrael
-
Hillel Yaffe Medical CenterCompletedUnfavorable Cervix for Induction of LaborIsrael
-
Cirbia Silva Campos TeixeiraCompletedCervical Cancer | Diagnoses Disease | Screening | HSIL of CervixBrazil
-
Antiva BiosciencesCompletedCervical Cancer | Cervical Intraepithelial Neoplasia | CIN | Human Papilloma Virus | Cervical Dysplasia | HSIL of Cervix | Cervical Neoplasm | HSIL | High-Grade Squamous Intraepithelial Lesions | High-grade Cervical Intraepithelial NeoplasiaUnited States, Australia
-
University Fernando PessoaRecruitingHSIL, High Grade Squamous Intraepithelial Lesions | AIN3 | AIN2Portugal
-
St. Louis UniversityTerminated
-
Tata Memorial HospitalCompletedCervical Cancer | Cervix Cancer | Cancer of Cervix | Cancer of the CervixIndia
-
Begona Martinez de TejadaRecruitingInduction of Labor | Unfavorable Cervix | Cervical Ripening | Mechanical MethodSwitzerland
Clinical Trials on NWRD08
-
Newish Technology (Beijing) Co., Ltd.RecruitingHigh-grade Squamous Intraepithelial Lesion (HSIL)China